Identification of active-site residues of the pro-metastatic endoglycosidase heparanase - PubMed (original) (raw)
. 2000 Dec 26;39(51):15659-67.
doi: 10.1021/bi002080p.
Affiliations
- PMID: 11123890
- DOI: 10.1021/bi002080p
Identification of active-site residues of the pro-metastatic endoglycosidase heparanase
M D Hulett et al. Biochemistry. 2000.
Abstract
Heparanase is a beta-D-endoglucuronidase that cleaves heparan sulfate (HS) and has been implicated in many important physiological and pathological processes, including tumor cell metastasis, angiogenesis, and leukocyte migration. We report herein the identification of active-site residues of human heparanase. Using PSI-BLAST and PHI-BLAST searches of sequence databases, similarities were identified between heparanase and members of several of the glycosyl hydrolase families (10, 39, and 51) from glycosyl hydrolase clan A (GH-A), including strong local identities to regions containing the critical active-site catalytic proton donor and nucleophile residues that are conserved in this clan of enzymes. Furthermore, secondary structure predictions suggested that heparanase is likely to contain an (alpha/beta)(8) TIM-barrel fold, which is common to the GH-A families. On the basis of sequence alignments with a number of glycosyl hydrolases from GH-A, Glu(225) and Glu(343) of human heparanase were identified as the likely proton donor and nucleophile residues, respectively. The substitution of these residues with alanine and the subsequent expression of the mutant heparanases in COS-7 cells demonstrated that the HS-degrading capacity of both was abolished. In contrast, the alanine substitution of two other glutamic acid residues (Glu(378) and Glu(396)), both predicted to be outside the active site, did not affect heparanase activity. These data suggest that heparanase is a member of the clan A glycosyl hydrolases and has a common catalytic mechanism that involves two conserved acidic residues, a putative proton donor at Glu(225) and a nucleophile at Glu(343).
Similar articles
- Mechanism of activation of human heparanase investigated by protein engineering.
Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkühler C. Nardella C, et al. Biochemistry. 2004 Feb 24;43(7):1862-73. doi: 10.1021/bi030203a. Biochemistry. 2004. PMID: 14967027 - Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. Levy-Adam F, et al. J Biol Chem. 2005 May 27;280(21):20457-66. doi: 10.1074/jbc.M414546200. Epub 2005 Mar 10. J Biol Chem. 2005. PMID: 15760902 - Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z, Bates M, Madura JD. Zhou Z, et al. Proteins. 2006 Nov 15;65(3):580-92. doi: 10.1002/prot.21065. Proteins. 2006. PMID: 16972282 - Heparanase: Historical Aspects and Future Perspectives.
Khanna M, Parish CR. Khanna M, et al. Adv Exp Med Biol. 2020;1221:71-96. doi: 10.1007/978-3-030-34521-1_3. Adv Exp Med Biol. 2020. PMID: 32274707 Review. - [The active site of human glucocerebrosidase: structural predictions and experimental validations].
Fabrega S, Durand P, Mornon JP, Lehn P. Fabrega S, et al. J Soc Biol. 2002;196(2):151-60. J Soc Biol. 2002. PMID: 12360744 Review. French.
Cited by
- Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.
Hermano E, Lerner I, Elkin M. Hermano E, et al. Cell Mol Life Sci. 2012 Aug;69(15):2501-13. doi: 10.1007/s00018-012-0930-8. Epub 2012 Feb 14. Cell Mol Life Sci. 2012. PMID: 22331282 Free PMC article. Review. - Fucoidan's Molecular Targets: A Comprehensive Review of Its Unique and Multiple Targets Accounting for Promising Bioactivities Supported by In Silico Studies.
Zayed A, Al-Saedi DA, Mensah EO, Kanwugu ON, Adadi P, Ulber R. Zayed A, et al. Mar Drugs. 2023 Dec 30;22(1):29. doi: 10.3390/md22010029. Mar Drugs. 2023. PMID: 38248653 Free PMC article. Review. - Heparanase: A Challenging Cancer Drug Target.
Coombe DR, Gandhi NS. Coombe DR, et al. Front Oncol. 2019 Nov 28;9:1316. doi: 10.3389/fonc.2019.01316. eCollection 2019. Front Oncol. 2019. PMID: 31850210 Free PMC article. Review. - Heparanase in cancer progression: Structure, substrate recognition and therapeutic potential.
Yuan F, Yang Y, Zhou H, Quan J, Liu C, Wang Y, Zhang Y, Yu X. Yuan F, et al. Front Chem. 2022 Sep 9;10:926353. doi: 10.3389/fchem.2022.926353. eCollection 2022. Front Chem. 2022. PMID: 36157032 Free PMC article. Review. - Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.
Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, Cohen-Kaplan V, Petcherski S, Avniel-Polak S, Eitan A, Hammerman H, Aronson D, Axelman E, Ilan N, Nussbaum G, Vlodavsky I. Blich M, et al. Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):e56-65. doi: 10.1161/ATVBAHA.112.254961. Epub 2012 Nov 15. Arterioscler Thromb Vasc Biol. 2013. PMID: 23162016 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials